The XV meeting of the Spanish Drug Discovery Network (SDDN) will take place at the Parc de Recerca Biomèdica de Barcelona (PRBB) on November 20th and 21st, 2023. This international conference has become an ideal networking forum for the early drug discovery community, both from Academia and Industry. Every year we select a limited number of topics with the idea to facilitate an “in-depth” discussion among professionals with very different backgrounds, but all focused on advancing the frontline of drug discovery and translational medicine research. This year, the programme will focus on three scientific areas that are continuously evolving and increasingly having an impact on drug discovery: Artificial Intelligence, Cell and Gene Therapies, and Precision Medicine. We will also include a session showcasing inspiring examples of successful Public-Private Collaborations in Drug Discovery. The meeting is open to companies which want to exhibit their products, services and technologies, as well as sponsoring the event.
The meeting is organized by the SDDN and by the Center for Genomic Regulation (CRG).
Xavier Barril (Universitat de Barcelona), Anabel Sanz (Centre for Genomic Regulation), Marjorie Pion (Health Research Institute Gregorio Marañón), Francesc Fernández (Almirall), Jordi Quintana (Chemotargets), Jorge Beleta (SDDN), Carme Pampín (GalChimia), Julio Martín (Freelance, Sciengement Lab), Arsenio Nueda (Almirall)
Session 1. The impact of AI-based tools and data science in Drug Discovery
Chair: Xavier Barril (Universitat de Barcelona, UB)
Session 2. Drug Discovery projects in public – private collaborations
Chair: Anabel Sanz (Center for Genomic Regulation, CRG)
Session 3. Using patient omics for the discovery of personalized medicines
Chair: Francesc Fernández (Almirall)
Session 4. Advanced Cell and Gene Therapies
Chair: Marjorie Pion (Health Research Institute Gregorio Marañón)
Discounts for early-bird registrations before 28th July 2023
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More